Navigation Links
Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
Date:8/8/2012

THOUSAND OAKS, Calif., Aug. 8, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a decision to stop the ganitumab (AMG 479) Phase 3 GAMMA  (Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas) trial following the recommendation of an independent Data Monitoring Committee (DMC) overseeing the trial.  Based on the review of a pre-planned interim analysis, the DMC concluded that the addition of ganitumab to gemcitabine is unlikely to demonstrate a statistically significant improvement in the primary endpoint of overall survival compared to gemcitabine alone. There were no safety concerns raised in the DMC review of the study. 

The GAMMA study is a randomized, multicenter, double-blind, Phase 3 trial to determine if ganitumab plus gemcitabine improves overall survival, compared to placebo plus gemcitabine, in the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.   

"These disappointing results underscore the difficulty of treating pancreatic cancer, which remains a major unmet medical need," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "We would like to thank the patients, caregivers and investigators for their participation and engagement in the study."

Amgen has communicated with regulatory authorities and is in the process of notifying study investigators that treatment with ganitumab should be discontinued in the GAMMA trial, as well as a separate ongoing Phase 2 trial in locally advanced pancreatic cancer.

Ganitumab is an investigational fully human monoclonal antibody that targets type 1 insulin-like growth factor receptor (IGF1R).

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
2. Amgen Completes Acquisition of KAI Pharmaceuticals
3. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
4. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
7. Amgen to Present at the Baird Growth Stock Conference
8. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
9. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
10. AHM Announces New SVP Product Delivery
11. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  Alere Inc. (NYSE: ... diagnostics, issued the following statement today in support of ... Bacteria. "As the global leader in rapid ... establishing a national strategy to address the serious threat ... work with the Administration on initiatives to promote the ...
(Date:9/19/2014)... and ORLANDO, Fla. , Sept. ... Inspire therapy continues to grow, with the publication of ... on-line in Otolaryngology – Head and Neck ... a worsening of both objective and subjective measures of ... attribute Inspire therapy for the reduction in obstructive sleep ...
(Date:9/19/2014)... ANGELES , Sept. 19, 2014  CytRx Corporation ... development company specializing in oncology, today announced that ... present at BioCentury,s 2014 NewsMakers in the Biotech Industry ... Eastern Time. The conference will take place at the ... . A live and archived webcast ...
Breaking Medicine Technology:Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3
(Date:9/19/2014)... 19, 2014 “Copay coupons,” a drug ... brand drugs among patients with prescription drug coverage, may ... a new report from the Department of Health ... Federal anti-kickback laws prohibit suppliers from offering side-payments to ... federal government. , The report highlights that two recent ...
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 On ... News at the Platinum PR and Top Places to ... in New York City. Camino received honorable mentions in ... Campaign” — for its work elevating Latina voices in ... incredible organization and be a part of its efforts ...
(Date:9/19/2014)... 2014 According to a report from ... blood-thinner Xarelto, named as defendants in several lawsuits filed ... moved the court to dismiss those suits because the ... connection with Philadelphia.* The cases include, for instance, Fontan ... Pa. Comm. Pls., Philadelphia Cty.), which was brought by ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- Although ... key health benefits, most middle-aged and older adults ... type of exercise, according to new research. ... the muscle-strengthening recommendations set by the Department of ... Strength is essential for promoting health and ...
(Date:9/19/2014)... MetroMD, a leading anti-ageing clinic has called its ... health. This therapy has grown tremendously across USA in the ... safe and dependable. It has far reaching benefits for ageing ... a very healthy and active lifestyle even beyond their middle ... senior therapist at MetroMD said, “HGH or Human Growth hormones ...
Breaking Medicine News(10 mins):Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2
... , This release is available in Spanish ... when we talk about a disease? What affects the ideas ... the University of Granada have developed a test ... disease. This advance will enable the development of clinical psychological ...
... (SACRAMENTO, Calif.) A study of the options for ... been treated for precancerous cervical lesions found that an ... strategy. Joy Melnikow, professor in the Department of ... screening strategies for the 500,000 American women diagnosed and ...
... WASHINGTON, Oct. 20 -- Scientists and engineers from around the ... Rochester, N.Y. next week to discuss some of the latest ... science, the development of new materials, and medicine. Journalists ... -- the 94th annual meeting of the Optical Society (OSA), ...
... Reporter , WEDNESDAY, Oct. 20 (HealthDay News) -- Researchers have discovered ... levels: Regular consumption of the world,s two most popular beverages may ... In fact, the latest research suggests that those who drink as ... may lower brain cancer risk by as much as 34 percent. ...
... The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical ... Ridley-Thomas and Anne-Merelie Murrell, president of Giroux Glass Company, Inc., ... the Terranea Resort in Rancho Palos Verdes. Supervisor ... Excellence Award for Community Service. Mrs. Murrell will be ...
... Oct. 20 (HealthDay News) -- A combination of animal and ... therapy that could ultimately help in the treatment of major ... levels of a brain protein known as p11. The study ... of feelings of reward, pleasure and satisfaction with positive life ...
Cached Medicine News:Health News:The impact of chronic diseases on patients also depends on their perception of the disease 2Health News:Conventional, annual Pap smear cost-effective follow-up after cervical lesion treatment 2Health News:Conventional, annual Pap smear cost-effective follow-up after cervical lesion treatment 3Health News:Colorful brains, cooling lasers, disease-detecting lights and more 2Health News:Colorful brains, cooling lasers, disease-detecting lights and more 3Health News:Colorful brains, cooling lasers, disease-detecting lights and more 4Health News:Colorful brains, cooling lasers, disease-detecting lights and more 5Health News:Colorful brains, cooling lasers, disease-detecting lights and more 6Health News:Colorful brains, cooling lasers, disease-detecting lights and more 7Health News:Colorful brains, cooling lasers, disease-detecting lights and more 8Health News:Colorful brains, cooling lasers, disease-detecting lights and more 9Health News:Colorful brains, cooling lasers, disease-detecting lights and more 10Health News:Colorful brains, cooling lasers, disease-detecting lights and more 11Health News:Colorful brains, cooling lasers, disease-detecting lights and more 12Health News:Can Coffee, Tea Lower Brain Cancer Risk? 2Health News:Can Coffee, Tea Lower Brain Cancer Risk? 3Health News:LA BioMed honors 2 leaders 2Health News:Animal Study Explores Potential Gene Therapy for Depression 2Health News:Animal Study Explores Potential Gene Therapy for Depression 3
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: